By the end of 2009, the European Chemicals Agency had completed 15 of 30 "compliance checks" initiated since registration dossiers started dribbling in under REACH, and almost half of its checks have inspired quality observation letters due to inadequacies, the agency says
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.
FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
A round up of the latest European consumer health exec moves: Hermes hires management board chair; Assosalute elects directors; Moberg appoints ex-Orkla Health CEO.
Personal care, EU government reps discussing a planned revision of the 2006 European Union Suncare Recommendation are pushing for a legally binding text, rather than the recommendation, and considering broadening the definition for sunscreen.
Bridget Dooling, law school professor who reviewed draft regulations from FDA and other agencies as OMB attorney, says history of federal court decisions in litigation challenging FDA’s interpretation of statutes points to judges typically defer to agency decisions based in science.
